The GENIE BioPharma Collaborative (BPC): A Flagship Drug Development Program
The AACR GENIE BioPharma Collaborative (BPC) is a pre-competitive initiative designed to curate high-quality oncology datasets that support drug development and biomarker discovery.
BPC Phase 1 & 2: Expanding Solid Tumor Cohorts
- 10 solid tumor cohorts with deep clinical annotation (~20,000 cases).
- Cohorts aligned with active drug pipelines for biomarker discovery & trial optimization.
- Industry partners can still join Phase 2 with a full two-year data embargo for early access.
BPC Phase 3: Next-Generation Data Expansion
Building on the success of Phase 2, Phase 3 introduces key enhancements:
- Expanded solid tumor cohorts with increased representation.
- New hematologic malignancies for broader clinical applications.
- Integration of digital pathology (WSI) data for AI-driven image analysis.
- Continuous data refresh cycles for real-time, high-fidelity datasets.
Total Cases in BPC Phase 3: ~43,500
Join BPC Phase 3 – Launching in FY 2026 (LINK TO FORM???)